MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/jgh3.12737

Медицинская библиотека · JGH open : an open access journal of gastroenterology and hepatology · 2022

Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection.

Nakabori Tasuku, Abe Yutaro, Higashi Sena, Hirao Takeru, Kawamoto Yasuharu, Maeda Shingo, Daiku Kazuma, Urabe Makiko, Kai Yugo, Takada Ryoji, Yamai Takuo, Ikezawa Kenji, Uehara Hiroyuki, Ohkawa Kazuyoshi

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND AIM: Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events in the liver. The risk of exacerbating liver injury is of concern in patients infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), as immunotherapy can damage liver function because of the immune response against viral antigens. We assessed the feasibility of immunotherapy in HBV- or HCV-infected patients.

METHODS

This retrospective study included 266 patients with persistent or past HBV infection, 26 patients seropositive for anti-HCV, and 820 patients with negative viral markers for HBV and HCV, who were treated with ICIs. ICI-induced liver injury and changes in virological markers were analyzed.

RESULTS

The occurrence rates of ICI-induced liver injury in the HBsAg-positive, anti-HBc-positive/anti-HBs-positive, and anti-HBc-positive/anti-HBs-negative groups were 12.5, 21.6, and 19.1%, respectively, which were comparable with those of the negative for HBV- and HCV-related markers group (20.9%). The frequency of any grade ICI-induced liver injury was different among the HCV RNA-positive (3/5; 60.0%), anti-HCV-positive/HCV RNA-negative (2/21; 9.5%), and negative for HBV- and HCV-related markers (171/820; 20.9%) groups (P = 0.045), with no significant difference in grade ≥2 ICI-induced liver injury. In patients with persistent infection, neither serum HBV DNA, HBsAg, nor HCV RNA level changed significantly during ICI treatment. One of five treatment-naïve HCV-infected patients required interruption of ICI treatment due to virus-related liver injury.

CONCLUSION

Immunotherapy is feasible for most cancer patients with chronic HBV or HCV infection; however, liver function and virological markers should be carefully monitored in treatment-naïve patients, especially those with HCV infection, during ICI treatment.

Для цитирования: Nakabori Tasuku, Abe Yutaro, Higashi Sena, Hirao Takeru, Kawamoto Yasuharu, Maeda Shingo, Daiku Kazuma, Urabe Makiko, Kai Yugo, Takada Ryoji, Yamai Takuo, Ikezawa Kenji, Uehara Hiroyuki, Ohkawa Kazuyoshi. Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection.. JGH open : an open access journal of gastroenterology and hepatology. 2022. DOI: 10.1002/jgh3.12737.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.